Avastin resubmission
Executive Summary
Genentech appears on target for a February user fee date on its resubmitted sBLA for Avastin (bevacizumab) as a first-line treatment for metastatic breast cancer in combination with paclitaxel. The firm announced the resubmission Aug. 24 and expects a six-month review. FDA requested an independent review of patient scans for progression-free survival in a "complete response" letter it sent to the firm Sept. 8 (1"The Pink Sheet" Oct. 2, 2006, p. 21). Genentech said the independent review results were consistent with its earlier positive findings...
You may also be interested in...
Genentech’s Avastin gets review panel
FDA's Oncologic Drugs Advisory Committee will review Avastin (bevacizumab) in combination with paclitaxel chemotherapy for patients who have not received chemotherapy for locally recurrent or metastatic breast cancer, Genentech announces Sept. 13. ODAC is scheduled to meet Dec. 4-5. Genentech resubmitted the sBLA in August, setting up a February 23, 2008 action date (1"The Pink Sheet" Aug. 27, 2007, In Brief). The resubmission followed a "complete response" letter issued by the agency in September 2006 that requested an independent review of patient scans for progression-free survival...
Roche Builds Off Oncology Foundation With Autoimmune, Metabolic “Pillars”
Roche views its autoimmune and metabolic disease programs as additional "therapeutic pillars" that will complement its existing strength in oncology
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.